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ABSTRACT 
In the motor system, botulinum toxin type A (BoNT/A) actions were classically attributed to 
its well-known peripheral anticholinergic actions in neuromuscular junctions. However, 
enzymatic activity of BoNT/A, assessed by detection of cleaved synaptosomal-associated 
protein 25 (SNAP-25), was recently detected in motor and sensory regions of the brainstem 
and spinal cord after toxin peripheral injection in rodents. In sensory regions, the function of 
BoNT/A activity is associated with its antinociceptive effects, while in motor regions we only 
know that BoNT/A activity is present. Is it possible that BoNT/A presence in central motor 
nuclei is without any function? In this brief review we analyze this question. Limited data 
available in the literature warrant further investigations of BoNT/A actions in motor nervous 
system. 
Keywords: botulinum toxin type A; Synaptosomal-associated protein 25; motor regions; 
central effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
Botulinum toxin serotype A (BoNT/A) is a presynaptic neurotoxin synthesized by anaerobic 
gram-positive rod-shaped bacterium Clostridium botulinum. Intoxication with neurotoxin 
causes botulism, the disease characterized by prevention of acetylcholine release at 
neuromuscular junctions resulting in flaccid paralysis of skeletal muscle, and paralysis of 
autonomic cholinergic synapses (Matak and Lacković, 2014). BoNT/A targets synaptosomal 
associated protein SNAP-25, an integral part of heterotrimeric soluble N – 
ethylmaleimidesensitive factor attachment protein receptor (SNARE) complex of proteins 
required for synaptic vesicle exocytosis (Blasi et al., 1993). A widely accepted belief is that 
BoNT/A actions in the motor nervous system are confined to peripheral nerve endings, which 
may explain its classical therapeutic and toxic paralytic effects. Symptoms of botulism are 
confined mostly to muscular and autonomic paralysis, and central effects similar to the ones 
exerted by tetanus toxin are not present. However, in the last decade, mounting experimental 
and clinical data suggest that BoNT/A may reach central nervous system (CNS) after toxin 
peripheral injection (Mazzocchio and Caleo, 2015). Up to now, the significance of BoNT/A 
axonal transport and enzymatic activity in central motor neurons is unknown. In present 
review we will discuss this question. 
 
Evidence for axonal transport of BoNT/A 
Starting point in this review are observations that cleaved SNAP-25 (cSNAP-25) product of 
BoNT/A enzymatic activity appears in facial nucleus in the brain stem (Antonucci et al., 
2008, Restani et al., 2012b) or motor regions of the spinal cord after peripheral injections of 
the toxin (Matak et al., 2012; Koizumi et al., 2014). Stringent analysis would reveal that 
evidence in favor of central effect of BoNT/A in motor regions of central nervous system 
(CNS) are indirect (Mazzocchio and Caleo 2014.). Ideally, the direct evidence would be to 
 isolate the BoNT/A molecule from CNS motor regions after toxin peripheral injection, 
demonstrate that it is enzymatically active, and that it has some pharmacological effect, which 
has not been done yet. However there are many types of indirect but convincing evidence, 
which will be discussed in following sections. 
Early experiments of Habermann (1974) and Wiegand et al. (1976) after toxin injection into 
calf muscle in rats and cats with I125-radioiodinated BoNT/A, demonstrated the gradual 
radioactivity ascent along the sciatic nerve, followed by appearance of radioactivity in motor 
ventral roots and spinal cord. Radioactivity redistribution into the axonal compartment 
ofmotor nerve was found after incubation of diaphragm and frog leg muscles with the toxin 
(Black and Dolly, 1986). The drawback of these experiments is that it is not known if 
radioactively labelled BoNT/A retained its enzymatic activity in the axonal compartment and 
central motor regions. 
In vitro several authors found that fluorescently labelled BoNT/A heavy chain and holotoxin 
are axonally transported in compartmentalized cultured neurons, with minor differences about 
which cellular compartment is responsible for toxin transport (Restani et al., 2012b; Wang et 
al., 2015; Bomba-Warczak et al., 2016). In compartmentalized culture of motor neurons 
Restani et al. (2012b) showed retrograde axonal transport of full toxins (BoNT/A and 
BoNT/E) and their heavy chains within non-acidic axonal compartments, which also 
transported tetanus toxin and neurotrophins. This study suggests that axonally transported 
BoNT/A might employ well known routes of retrograde axonal transport similar to the ones 
used by other toxins and signaling molecules. A similar study with fluorescently labeled 
BoNT/A heavy chain (Hc) was performed by Wang et al. (2015) in compartmentalized 
culture of hippocampal motor neurons. By employing mCherry-labelled Hc, they 
demonstrated retrograde movement of the toxin within retrogradely transported organelles. 
After injection into the mouse hind-limb, occurrence of fluorescently-labelled Hc was also 
demonstrated in soma of spinal cord motoneurons. Unlike Restani et al. (2012b), they 
demonstrated the presence of toxin within acidic axonal compartments corresponding to 
autophagosomes, and subsequent movement into lysosomal compartments of the cell soma 
(Wang et al., 2015). The weakness of these experiments is that it is not known whether the 
movement of labelled toxin represents only the movement of BoNT/A Hc alone, as the light 
chain might be translocated into the cytoplasm. The argument that BoNT/A is transported in a 
functional form in both mentioned studies is the immunodetection of cSNAP-25 in the 
neuronal soma compartment (Restani et al., 2012b; Wang et al.2015). 
Recently, Bomba-Warczak et al (2016) provided in vitro evidence that retrogradely 
transported BoNT/A, BoNT serotype D, and tetanus toxin are secreted from the soma into the 
extracellular fluid, from where they can be recaptured and enter second-order neurons. The 
authors used microfluidic chambers with separated axons and soma of cultured neurons and 
employed labeled toxin molecules and cSNAP-25 detection. Toxins were applied to the axon 
chamber. Transsynaptic passage of BoNT/A and other toxins was inhibited by adding excess 
of their respective Hc or neutralizing antibodies. Thus, during the transsynaptic passage, 
BoNT/A is exposed to the extrasynaptic milieu. Entering the second order neurons by 
receptor moiety dependent process requires that the entire molecule is transported and 
released. This study suggests the existence of cellular mechanisms for the axonal transport of 
BoNT/A holotoxin and transcytosis within neurons. However, it has to be noted that for 
transcytosis experiments the authors employed high concentration of BoNT/A (30 nM) in the 
microfluidic chamber containing the axons (Bomba-Warczak et al., 2016). This concentration 
is higher than picomolar concentrations needed to produce synaptic blockade and SNAP-25 
cleavage in vitro (Scherf et al., 2014; Hubbard et al., 2015). 
 
Detection of truncated SNAP-25 fragments in CNS after peripheral toxin injection 
 
In vivo convincing evidence of axonal transport of active BoNT/A molecules was 
demonstrated with detection of cSNAP-25 in central motor regions. When BoNT/A was 
injected into the rat whisker pad, hind paw, gastrocnemius, or sciatic nerve, cSNAP-25 was 
detected in the corresponding motor regions mostly surrounding the primary motor neurons 
(Antonucci et al., 2008; Restani et al., 2012b; Matak et al., 2012; Koizumi et al., 2014). By 
employing detection of cSNAP-25 fragment by Western blot and immunohistochemistry, 
Antonucci et al. (2008) showed that after BoNT/A injection into the rat whisker pad (135 pg 
of 150 kDa toxin), a strong signal of cSNAP-25 immunoreactivity was detected in rat 
ipsilateral facial nucleus. Importantly, after BoNT/A and tetanus toxin application into the rat 
whisker pad both toxins proteolytic activity appeared in the brainstem with a similar time 
course that paralleled the peripheral spastic paralysis for tetanus toxin, but lagged behind the 
onset of flaccid paralysis for BoNT/A. This demonstrates similarity of axonal transport of 
both toxins but difference in appearance of peripheral effect, and finally behavioral effect of 
BoNT/A activity in CNS reminded unknown (Restani et al., 2012b). The study of Antonucci 
et al. (2008) was met with skepticism because of the dose employed, the use of nontherapeutic 
toxin preparation, and the lack of antibody characterization for specificity to 
cSNAP-25 (Aoki and Francis, 2011). Subsequently it was demonstrated that the antibody 
employed in study of Antonucci et al. (2008) was indeed specific for cSNAP-25, since it 
bound to the 24 kDa Western blot band corresponding to cSNAP-25 in toxin-injected tissue 
(Matak et al., 2011). The appropriate position of 24 kDa band was confirmed with referent 
antibody which recognizes both uncleaved and cSNAP-25 (Matak et al., 2011). Moreover, in 
further study BoNT/A-cSNAP-25 fragments were detected in dorsal horn, and much stronger 
signal was detected in the ventral horn of the spinal cord after low dose toxin injections into 
the gastrocnemius muscle or sciatic nerve (5-10 mouse LD50 doses per kg (U/kg)). The 
immunoreactivity to cSNAP25-was situated in nerve terminals in contact with α-motoneuron 
 
cell bodies and in more distant neuronal processes (Matak et al., 2012).The cSNAP-25 
collocalised with cholinergic terminals surrounding the motoneuronal cells after BoNT/A 
injection into the hind paw i.e. near plantar muscles (Matak et al., 2012). Since α- 
motoneurons innervating plantar muscles do not have recurrent axon collaterals (Cuilheim 
and Kellert, 1978), we hypothesize that cholinergic terminals exhibiting cSNAP-25 did not 
reside in motor neurons innervating the plantar muscles. Thus, BoNT/A-cleaved SNAP-25 
immunoreactivity might be situated in second order synapses within the ventral horn, 
indicating possible transsynaptic effect of of BoNT/A. By employing high dose of BoNT/A 
(10 U), Koizumi et al. (2014) similarly demonstrated the occurrence of BoNT/A-cleaved 
SNAP-25 in corresponding spinal cord segment. The cSNAP-25 was visible both in ipsilateral 
and contralateral ventral and dorsal horn. This finding implies transcytosis and neuronal 
spread through commissural interneurons to contralateral side; however, at high peripheral 
doses (10 U). In our experiments (Matak et al., 2012), occurrence of cSNAP-25 was restricted 
to ipsilateral segment of the spinal cord. cSNAP-25 was also observed in parts of CNS distant 
to the site of toxin central injection: a. after unilateral intrahippocampal toxin injection, 
cSNAP-25 was found in contralateral hippocampus, which was accompanied by suppression 
of neuronal activity on that side. (b.) detection of cSNAP-25 in retina after toxin injection into 
superior colliculus, accompanied by suppression of cholinergic transmission in retina 
(Antonucci et al., 2008; Restani et al., 2012a), and occurrence of cSNAP-25 in superior 
colliculus after BoNT/A injection into retina (Restani et al. 2011). 
Investigating the transport of BoNT/A Wang et al. (2015) mentioned the possibility that 
cSNAP-25 could also be transported from periphery to soma for degradation. Thus, 
occurrence of cSNAP-25 in the CNS might not necessary reflect BoNT/A activity but 
cSNAP25 transported from periphery. However, immunohistochemically, most of cSNAP-25 
was found in nerve fibers and not in cell soma where degradation of cSNAP-25 could be 
 
expected (Antonucci et al., 2008; Matak et al., 2012). Moreover, according to already 
described experiments of Caleo group (Antonucci et al. 2008; Restani et al., 2012a), it would 
imply that such truncated protein is transcytosed and axonally transported not only 
retrogradely but for example anterogradely from retina along the optic nerve, and transcytosed 
to second-order synapses in the superior colliculus. For now there is no experimental evidence 
for that. In experiments by Antonucci et al. (2008), optic nerve transection followed by 
application of shortly acting BoNT serotype E in the eye transiently depleted the 
BoNT/Acleaved 
SNAP-25 epitope in the retina. Upon completion of BoNT/E effects, BoNT/Atruncated 
SNAP-25 re-appeared in the distant synapses, suggesting the long-term presence of 
axonally transported BoNT/A protease (Antonucci et al., 2008; Restani et al., 2011). Similar 
experiments have not yet been performed in the motor system. 
 
Evidence for central effect of BoNT/A after its peripheral application: central 
antinociceptive activity of BoNT/A 
For now, physiological or behavioral effect of BoNT/A in central motor system after toxin 
peripheral injection is not known. So far the most convincing evidence for functional 
consequences of axonally transported of BoNT/A arose from behavioral studies or 
combination of behavioral and immunohistochemical experiments in sensory system. In 
number of behavioral experiments we (Bach-Rojecky et al., 2005, 2008, 2009, 2010a, 2010b, 
Bach Rojecky and Lacković 2009; Matak and Lacković 2014; Drinovac et al., 2016) and the 
group of Pavone and Luvisetto (Luvisetto et al, 2006, 2007, 2015; Marinelli et al., 2012; 
Pavone and Luvisetto 2010; Mika et al., 2011) demonstrated that antinociceptive effect of 
BoNT/a cannot be explained solely by its peripheral action. For example, nerve application of 
axonal transport blocker colchicine prevented antinociceptive effect of BoNT/a in different 
models of peripheral pain or intrathecal application of BoNT/a is more effective than 
peripheral one. Futhermore, bilateral pain associated with experimental diabetes (Bach- 
Rojecky et al., 2010) or cytostatic induced neuropathy (Favre-Guilmard et al., 2009), acidic 
saline (Bach-Rojecky and Lacković, 2009) or carrageenan-induced mirror pain (Drinovac et 
al., 2016) can be bilaterally reduced by unilateral injection of BoNT/A in rats. Most 
convincing are the experiments demonstrating that behavioral influence of BoNT/A is closely 
associated with appearance of cSNAP-25 in the CNS (Matak et al., 2011; Filipović et al., 
2012; Wu et al., 2016). In trigeminal regions we found that extracranially injected BoNT/A 
prevents neurogenic inflammation in the cranial dura, which is associated with appearance of 
cSNAP-25 collocalised with calcitonin gene-related peptide (CGRP) in nerves innervating the 
dura mater. 
 
Physiological effects of BoNT/A in motor nervous system possibly related to its direct 
central effects 
Experimental studies in cats suggested BoNT/A distant effects in abducens motoneuron 
nucleus upon toxin injection into the lateral rectus muscle (Moreno-Lopez et al., 1997; Pastor 
et al., 1997). BoNT/A dose of 3 ng inhibited the discharge of motoneurons and induced 
synaptic alterations such as build-up of presynaptic vesicles in synapses connected to 
motoneuron cell bodies. Interestingly, 0.3 ng BoNT/A dose, which paralyzed the muscle, 
exerted only subtle changes in the motoneuron discharge pattern (Moreno-Lopez et al., 1997; 
Pastor et al., 1997). The authors hypothesized that BoNT/A underwent axonal transport in 
abducens motor neurons upon high intramuscular doses, and then enters synapses connected 
to motor neuronal cell bodies. 
Surprisingly, suggestions of possible BoNT/A central effects in motor regions came from 
studies in patients (Mazzocchio and Caleo 2015). Some subtle toxin effects on H reflex, 
suggesting action on the CNS, have been observed in individuals suffering from botulism 
(Tyler et al., 1963). 
Wohlfarth et al., (2001) reported reductions in F-wave measured in distant, non-injected 
muscles in patients treated for cervical dystonia, indicating distant motoneuronal changes in 
excitability. The authors hypothesized that mentioned results might result 
from BoNT/A effect upon muscle spindles, however, it was unlikely that BoNT/A was 
reaching the remotes spindles in sufficient amounts to reduce their activation (Wohlfart et al., 
2001). As another option, the authors hypothesized a central effect of BoNT/A upon 
motoneuronal cell bodies, which reduces their excitability (Wohlfarth et al., 2001). 
More recently, Marchand-Pauvert et al. (2013) measured recurrent inhibition in distant 
muscles of patients treated for lower limb spasticity. In their setup, recurrent inhibition was 
evoked by stimulation of toxin-uninjected muscles. They discovered that BoNT/A injected 
into soleus muscle reduces the recurrent inhibition in biceps femoris muscle. They argued that 
peripheral effects on muscle spindles in injected muscle would have minimal effect on 
recurrent inhibition in distant muscle. A more proximal, central site of action was suggested 
since recurrent collaterals of BoNT/A injected soleus α-motoneurons innervate the Renshaw 
cells which control the biceps femoris motoneurons. Thus, it is suggested that BoNT/A, 
following its axonal transport, blocked the cholinergic synapse between recurrent collaterals 
of soleus α- motoneurons and Renshaw cells innervating the biceps femoris (Marchand- 
Pauvert et al., 2013; Mazzocchio and Caleo 2015). Similar findings were obtained in 
quadriceps muscle of stroke-related spastic patients after BoNT/A injection into soleus muscle 
(Aymard et al., 2013). 
 
BoNT/A effects on gene expression in motor regions 
In motor regions, BoNT/A might induce additional effects at pharmacologically relevant 
doses, not necessarily connected only to prevention of neurotransmitter release (Matak and 
Lacković, 2015). There is a possibility that long-term presence of BoNT/A molecule in 
neurons might enable an indirect or direct BoNT/A interaction with gene expression and 
other cellular mechanisms (Scherf et al., 2014; Mazzocchio and Caleo, 2015). Bilateral 
upregulation of CGRP and enkephalin m-RNA expression in corresponding spinal cord 
segments and more distant spinal cord regions has been observed after local intramuscular 
BoNT/A injection of sub-systemic doses (Humm et al., 2000; Jung et al., 1997; Zhang et 
al.,1993). Increased nitric oxide synthase activity was observed in facial motoneurons after 
toxin whisker pad injection (Mariotti and Bentivoglio, 1996). After BoNT/A injection into the 
soleus, a widespread reduction of brain-derived neurotrophic factor (BDNF) and increase of 
neurotrophin-3 (NT3) mRNA and protein was observed in the ipsilateral spinal cord (Gomez- 
Pinilla et al., 2004). BoNT/A induced a reduced expression of synapsin I mRNA in the 
ipsilateral spinal cord (Gomez-Pinilla et al., 2004). Up to now, it remains completely 
unknown how does peripheral BoNT/A injection induce such widespread changes on gene 
expression, and whether any of these effects contribute to toxin’s activity in the motor 
nervous system. However, critical comment to possible effect of BoNT/A on gene 
expressions is that it is widely known that every denervation induces plastic changes in the 
central nervous system. Thus, specificity of mentioned effects requires further investigations. 
 
 
 
Possible effects of BoNT/A on peripheral γ-motor nerve endings and muscle spindle 
afferents mediating indirect central actions 
BoNT/A used for treatment of focal muscle hyperactivity movement disorders induces muscle 
relaxation and relief of spastic or involuntary contractions. General opinion is that BoNT/A 
induced local effects fully account for its beneficial activity in these disorders. However, the 
beneficial duration of action of BoNT/A on spastic or involuntary contractions does not 
necessarily concur or follow the muscle-relaxing effects, suggesting a more complex 
mechanism of action (Rosales and Dressler, 2010; Kaňovský and Rosales, 2011; Mazzocchio 
and Caleo 2015 ). One of the suggested mechanisms of action is modification of stretch reflex 
by toxin’s indirect action on firing of muscle spindle afferents which provide proprioceptive 
control for the muscle length and tension (Rosales and Dressler, 2010;Kaňovský and Rosales, 
2011). This is based on only few experimental studies assessing the BoNT/A effects on 
muscle spindles. Filippi et al. (1993) examined spindle afferent discharge 
in trigeminal mesencephalic nucleus shortly after injecting the toxin into the rat 
massetermuscle area densely populated with muscle spindles. They observed a fast onset 
reduction of afferent discharge, but jaw muscle tension was not affected during the 
measurement (up to 20 min after the BoNT/A injection). As explanation of these 
observations, it was proposed that BoNT/A blocked the intrafusal fibers, but not the extrafusal 
fibers mediating the muscle tension. However, the results of this study have to be considered 
with caution, since authors used high single dose of BoNT/A (140 mouse lethal 
LD50 dose units (U)). 
The effect of BoNT/A on both extrafusal and intrafusal fibers was studied histologically by 
Rosales et al. (1996). Type I slow and type II fast extrafusal muscle fibers, as well as Bag1 
and Bag2 intrafusal muscle fibers (weakly and strongly stained for acidic and alkali ATP-ase) 
exhibited a reduction in fiber diameters after 14 days but not on day 4 post toxin injection 
compared to control. Both extrafusal and intrafusal muscles had increased end-plate length 14 
days post BoNT/A. The authors concluded that the changes in extrafusal and intrafusal 
muscles are similar, and occur at the same time. However, Gracies (2004) pointed out that 
muscle spindles are encapsulated and it is not known whether large BoNT/A molecule (900 
kDa complex) can penetrate it. Overall, based on available data it was questioned whether 
BoNT/A actually affects the γ-motor neurons, or the described results are an indirect 
consequence of blockade of α-motor neuron activity (Gracies, 2004). 
It is also not known whether BoNT/A might affect Ia and II type afferents directly, rather than 
indirectly through its effect on intrafusal fibers from γ-motoneurons. A recent study by Caron 
et al. (2015) suggests that the mechanosensitive function of type Ia and II primary afferents 
recovers in parallel with the regain of muscular function, while the impaired function of 
metabosensitive sensory afferents (e.g. such as the ones detecting lowered pH upon fatigue) 
persists longer than the muscular recovery period. Thus, for now there is no definite evidence 
of BoNT/A direct action upon Ia and II proprioceptive afferents. 
In addition, it was suggested that BoNT/A might have indirect effects on cortical excitability 
via muscle spindle fibers (Kaňovský and Rosales, 2011). BoNT/A normalizes the impaired 
cortical and subcortical representations of the treated muscles in dystonic patients, and also in 
other CNS regions, such as supplementary motor areas and dorsal premotor cortex (Opavský 
et al., 2011). However, similar cortical changes are not visible in first time-treated dystonic 
patients, even if the first BoNT/A application is beneficial (Nevrly et al., 2014). This suggests 
that robust cortical changes develop with delay after long-term regular BoNT/A treatment 
(Nevrly et al., 2014). 
To explain observations about BoNT/A action on central motor system some authors assumed 
that BoNT/A affects the functional organization of the motor (Curra et al., 2004) and sensory 
system (Aoki and Francis, 2011) in the CNS indirectly through peripheral mechanisms. Caleo 
et al. (2009) and Mazzocchio and Caleo (2014) hypothesize that BoNT/A action in the CNS 
could contribute to those observations. Bearing in mind the brain ability for plastic changes 
this remains a possibility. On the other hand, discoveries in vitro that neurons possess 
mechanisms for axonal transport of BoNT/A holotoxin and transcytosis (Bomba-Warczak et 
al., 2016) and discoveries in vivo that after peripheral application BoNT/A appears in motor 
as well as sensory regions of the CNS (Antonucci et al., 2008; Matak et al., 2012) cannot rule 
out direct action of peripherally applied BoNT/A on CNS. However, for motor system 
evidence for physiological effect of BoNT/A is indirect and thus, it remains unknown whether 
cortical changes play a causative role in muscle-relaxing actions of BoNT/A, or what might 
be the long term effects of gene expression in motor regions. 
 
Conclusion 
Already a large number of behavioral and immunohistochemical experiments or combination 
of the two demonstrate axonal transport of BoNT/A from periphery to central sensory system 
and its association with antinociceptive effect of BoNT/A. Concerning motoric system 
strongest evidence suggesting central effect of BoNT/A after peripheral application is 
immunohistochemical demonstration of its enzymatic activity in motoric regions. Presence of 
cSNAP-25 primarily in nerve fibers and not in cell bodies, evidence in vitro and in vivo for 
axonal transport and transcytosis suggest that SNAP-25 is indeed cleaved in the CNS and not 
transported by autophagosome or other mechanism from peripheral nerve endings to be 
destroyed in cell soma. Here we reviewed some indirect evidence for such functions. 
Application of BoNT/A to experimental animals and to millions of people suggest that 
BoNT/A effect in the CNS does not interfere with its basic effect on muscular paralysis. Most 
probably central BoNT/A participate in some long term effect or in fine tuning of motor 
activity and we hypothesize that it might be specifically important in pharmacotherapy of 
different movement disorders. Finally, to put it most simple; it seems difficult to imagine that 
abundant presence of botulinum toxin enzymatic activity in motor regions of the CNS is 
without a function. 
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